Crossbow Therapeutics, Inc., a biotechnology company dedicated to improving the lives of people with cancer, has secured $77.0 million in new investment capital. The company is focused on unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. Its proprietary T-Bolt™ therapies represent a next-generation class of easily assembled immunotherapies designed for high-precision targeting of previously unreachable cancer cell targets.
This significant funding round will support Crossbow Therapeutics in its mission to develop innovative treatments. The company's efficient and selective approach aims to target the entire universe of cancer proteins, thereby dramatically expanding the potential of antibody therapy to address many types of cancer. The capital infusion underscores investor confidence in Crossbow's platform and its potential to deliver transformative oncology solutions.
Crossbow Therapeutics plans to deploy the newly raised capital to advance its T-Bolt™ therapy platform. The funds are also earmarked for expanding its pipeline of TCR-mimetic antibodies and accelerating the preclinical and clinical development of its novel immunotherapies. This investment is crucial for progressing its research and development efforts, aiming to bring its targeted therapies closer to patients.
The $77.0 million in funding positions Crossbow Therapeutics for continued growth and innovation within the competitive oncology landscape. The company is focused on leveraging this capital to further validate its technology and expand its therapeutic reach. This strategic investment is expected to enable Crossbow to strengthen its capabilities and pursue its long-term objective of addressing unmet needs in cancer treatment.
